论文部分内容阅读
医药产业关系到每个国民的切身利益和生命健康,对社会经济稳定发展的作用不容忽视。各国政府在医药产业内的各领域都规定了一定的药事管理法规,设置了较高的准入门槛。近年来,伴随GAP与GMP认证工作的展开,我国医药产业整体得到优化,产业集中度增强,市场运行更加规范。然而,在GAP与GMP认证的实施中仍存在某些问题。本文结合医药产业存在“外部性”和“垄断性”的经济学特征,谈谈政策干预对产业的影响以及如何应对政策可能对产业发展导致的不利影响。
The pharmaceutical industry is vital to the immediate interests and health of every citizen and plays a vital role in the stable social and economic development. Governments in various fields within the pharmaceutical industry have stipulated certain regulations on the administration of pharmaceuticals and set a relatively high threshold for admittance. In recent years, along with the GAP and GMP certification work, China’s pharmaceutical industry has been optimized as a whole, industry concentration increased, the market more standardized operation. However, there are still some issues in the implementation of GAP and GMP certification. Based on the economic characteristics of “externality” and “monopoly” in the pharmaceutical industry, this article talks about the impact of policy intervention on the industry and how to deal with the possible adverse impact of the policy on industrial development.